Compare AbCellera Biologics Inc (ABCL) vs Plby Group Inc (PLBY) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

PLBY trades at $1.18, down 6.35% today, reflecting ongoing volatility. The stock shows mixed signals with a bearish technical trend but bullish oscillators like RSI at oversold levels. Fundamentally, the company has improved its net loss significantly from -$278M in 2022 to -$13M in 2025, with revenue stabilizing around $121M. Recent news highlights inclusion in Russell indexes and a share repurchase program, signaling management confidence. Cash flow turned positive in 2024-2025 after years of negative operational cash flow, though high debt remains a concern.

The outlook is cautiously optimistic due to improving EBITDA and analyst buy ratings (75%), but risks include persistent net losses, high debt-to-asset ratio near 60%, and competitive pressures in leisure branding. Investment appeal hinges on continued margin improvement and debt management, with current valuation metrics like P/S of 1.05 suggesting potential if execution succeeds.